Gemcitabine

Generic Name: Gemcitabine

Brand Names: Gemzar

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₁F_₂N_₃O_₄

CAS Number: 95058-81-4

Unique Ingredient Identifier: B76N6SBZ8R

Background: Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...

Indication: Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.

In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...

Associated Conditions: Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: cisplatin
Drug: paclitaxel
Drug: fluorouracil
Radiation: radiation therapy
Drug: Gemcitabine
Procedure: Radical cystectomy

First Posted Date: 2003-03-07

Last Posted Date: 2018-06-15

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 97

Registration Number: NCT00055601

Locations: 🇺🇸
Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States
🇺🇸
LDS Hospital, Salt Lake City, Utah, United States

A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2003-02-24

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 130

Registration Number: NCT00055250

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5pm Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Lakeland, Florida, United States

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Urethral Cancer

Interventions: Drug: carboplatin
Drug: gemcitabine
Drug: paclitaxel
Procedure: surgery

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-27

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 77

Registration Number: NCT00045630

Locations: 🇺🇸
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Hurley Medical Center, Flint, Michigan, United States

and more 124 locations

Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: gemcitabine

First Posted Date: 2003-01-27

Last Posted Date: 2017-01-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00003744

Locations: 🇺🇸
Lahey Clinic, Burlington, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 3 locations

A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00001449

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas

Phase 1

Completed

Conditions: Gastrointestinal Neoplasms
Pancreatic Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00001431

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas

Phase 2

Completed

Conditions: Pancreatic Cancer
Pancreatic Neoplasm

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00005926

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Pulmonary Neoplasms
Neoplasms, Lung

First Posted Date: 2002-08-06

Last Posted Date: 2006-07-19

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00042679

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Phase 3

Completed

Conditions: Pancreatic Neoplasms
Metastases, Neoplasm

First Posted Date: 2002-05-03

Last Posted Date: 2006-07-19

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00035035

A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Phase 2

Completed

Conditions: Urologic Neoplasms

First Posted Date: 2002-05-01

Last Posted Date: 2006-07-19

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00034593

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Homburg/Saar, Germany
🇫🇷
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.", Paris Cedex 14, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy